Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bffdd255ff33c2031be964c4257cbbcc0> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bffdd255ff33c2031be964c4257cbbcc0 NCIT_P378 "NCI" @default.
- Bffdd255ff33c2031be964c4257cbbcc0 type Axiom @default.
- Bffdd255ff33c2031be964c4257cbbcc0 annotatedProperty IAO_0000115 @default.
- Bffdd255ff33c2031be964c4257cbbcc0 annotatedSource NCIT_C186403 @default.
- Bffdd255ff33c2031be964c4257cbbcc0 annotatedTarget "An orally available inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, ivarmacitinib binds to and inhibits JAK1, thereby preventing JAK-dependent signaling. This may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types. Additionally, JAK1 may be a primary driver of STAT3 phosphorylation and signaling, which plays a role in neoplastic transformation, resistance to apoptosis, tumor angiogenesis, metastasis, immune evasion, and treatment resistance." @default.